{
    "clinical_study": {
        "@rank": "11686", 
        "arm_group": {
            "arm_group_label": "FOLFIRINOX", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV)   200 mg/m2 IV over 2 hours on Day 1;  followed by  5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion."
        }, 
        "brief_summary": {
            "textblock": "This phase \u2161 study was designed to evaluate the efficacy and safety of mFOLFIRINOX as\n      first-line treatment for metastatic pancreatic cancer in China."
        }, 
        "brief_title": "mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Although FOLFIRINOX regimen was recently presented to be effective for metastatic pancreatic\n      cancer in selected patients who have good physical condition, there is still insufficient\n      evidence on this regimen in treating patients with metastatic pancreatic cancer in China.\n      Since for many tumors, different races may show different responses to the same regimen, we\n      design this open, multicenter phase \u2161 study to evaluate the the efficacy and safety of\n      mFOLFIRINOX as first-line treatment for metastatic pancreatic cancer in China."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients have provided a signed Informed Consent Form\n\n          -  ECOG performance status of 0-1\n\n          -  BMI \u2265 18.5\n\n          -  Age: 18-65 years old\n\n          -  Histologically confirmed diagnosis of metastatic pancreatic cancer\n\n          -  No prior palliative chemotherapy\n\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1\n             criteria\n\n          -  Life expectancy \u2265 3 months\n\n          -  Patient has adequate bone marrow and organ function\n\n               -  Absolute Neutrophil Count (ANC) \u2265 2.0 x 109/L\n\n               -  Platelets \u2265 90 x 109/L\n\n               -  Hemoglobin \u2265 90 g/L\n\n          -  Patient has adequate liver function\n\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\n                  liver metastasis)\n\n               -  Serum bilirubin \u2264 1.2 x ULN\n\n          -  Creatinine \u2264 1.25 times ULN\n\n          -  Good compliance\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women\n\n          -  Brain metastasis or only with bone metastasis.\n\n          -  Patients with severe gastrointestinal hemorrhage which need frequent blood\n             transfusions.\n\n          -  Refuse to take appropriate contraceptive measures (including male patients).\n\n          -  Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.\n\n          -  Severe systemic disease out of control such as unstable or uncompensated respiratory,\n             cardiac, liver, renal diseases.\n\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\n             enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in\n             situ).\n\n          -  Psychiatric illness that would prevent the patient from giving informed consent.\n\n          -  Patient is concurrently using other antineoplastic agent\n\n          -  Patient has used investigational antineoplastic agent within 4 weeks prior to entry.\n\n          -  Known HIV-positivity.\n\n          -  No history of chronic diarrhea, nausea or vomit.\n\n          -  No \u2265 grade 2 sensory peripheral neuropathy.\n\n          -  A history of transmural myocardial infarction (within 6 months prior to entry),\n             congestive heart failure, and unstable angina.\n\n          -  Infectious disease or inflammation with body temperature \u2265 38 \u2103."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028806", 
            "org_study_id": "PAN-321"
        }, 
        "intervention": {
            "arm_group_label": "FOLFIRINOX", 
            "description": "Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.", 
            "intervention_name": "mFOLFIRINOX", 
            "intervention_type": "Drug", 
            "other_name": [
                "Oxaliplatin", 
                "Irinotecan", 
                "Leucovorin", 
                "5-Fluorouracial"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Leucovorin", 
                "Levoleucovorin", 
                "Oxaliplatin", 
                "Irinotecan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 4, 2014", 
        "location": {
            "contact": {
                "email": "liyh@sysucc.org.cn", 
                "last_name": "Li Yuhong, MD, Ph D"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen University Cancer Center"
            }, 
            "investigator": {
                "last_name": "Li Yuhong, MD, Ph D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase \u2161 Trial to Investigate the Efficacy and Safety of mFOLFIRINOX in Patients With Metastatic Pancreatic Cancer in China", 
        "overall_contact": {
            "email": "liyh@sysucc.org.cn", 
            "last_name": "Li Yuhong, MD, Ph D"
        }, 
        "overall_official": {
            "affiliation": "Sun Yat-sen University", 
            "last_name": "Li Yuhong, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease control rate", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028806"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Yuhong Li", 
            "investigator_title": "MD, Ph D", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "From the date of first drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From the date of first drug administration until the date of death, assessed up to 60 months"
            }, 
            {
                "description": "Safety data will be assessed at each study  visit using NCI CTCAE version 3.0", 
                "measure": "Number of participants with AEs and SAEs  as a measure of Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Each follow up visit, assessed up to 24 weeks"
            }, 
            {
                "description": "Quality of life will be assessed at each study using EORTC QLQ-C30", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "Each follow up visit, assessed up to 24 weeks"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhong Li", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}